

Remarks

Claims 54-58 and 71-75 were pending in the subject application. By this Amendment, applicants have canceled Claim 75 without prejudice or disclaimer, and amended Claim 54.

Applicants maintain that the amendments to Claim 54 do not raise an issue of new matter and are fully supported by the application as filed. In addition, applicants maintain that Claim 54 is supported by parent U.S. Application No. 08/531,832, now U.S. Patent No. 6,001,964. Support for Claim 54 can be found in U.S. Patent No. 6,001,964 at least as follows. The claimed peptide is described in Column 4, lines 14-19. The D-optical isomer is described in Column 3, line 55. Treatment of a subject with the peptides is described, for example, in Column 7, lines 30-38. Glomerulonephritis is described in Column 1, line 34. Accordingly, entry of the amendment is respectfully requested.

Rejection under 35 U.S.C. §112, first paragraph

Claims 54-58 and 71-75 are rejected under the written description requirement of 35 U.S.C. §112, first paragraph. In view of the amendment made hereinabove, applicants respectfully request that the Examiner reconsider and withdraw this ground of rejection.

Information Disclosure Statement

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the references that are listed on the attached form PTO/SB/08B. This IDS is being submitted to make of record in the subject application references that were already considered in parent U.S. Application No. 08/531,832, now U.S. Patent No. 6,001,964, from which the subject application claims the benefit of its filing date under 35 U.S.C. §120. Accordingly, pursuant to 37 C.F.R. §1.98(d), copies of previously cited or submitted references are not included with this

Applicants: Bruce D. Gaynor et al.
Appln No.: 08/833,838
Filed: April 10, 1997
page 5 of 5

Information Disclosure Statement. Applicants are submitting the subject Information Disclosure Statement pursuant to 37 C.F.R. §1.97(b)(4) with the filing of a RCE. Accordingly, no fee is deemed necessary in connection with the filing of this Information Disclosure Statement.

Conclusions


In light of the amendment and remarks made hereinabove, applicants respectfully request withdrawal of the rejection under 35 U.S.C. §112, first paragraph, and passage of the claims to allowance. If there are any minor matters preventing allowance of the subject application, applicants request that Examiner Ewoldt contact the undersigned attorney.


A check for \$455.00 is enclosed to cover the following fees for a small entity: \$60.00 fee for a one month extension of time and \$395.00 fee for filing a Request for Continued Examination. No other fee is deemed necessary in connection with the submission of this reply. However, if any other fee is required to maintain the pendency of the subject application, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 01-1785.

Respectfully submitted

AMSTER, ROTHSTEIN & EBENSTEIN LLP
Attorneys for Applicants
90 Park Avenue
New York, NY 10016
(212) 336-8000

Dated: New York, New York
January 6, 2005

By: 
Alan D. Miller
Registration No. 42,889



Substitute form 14-000-00

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	08/833,838
Filing Date	April 10, 1997
First Named Inventor	Bruce D. Gaynor
Art Unit	1644
Examiner Name	Gerald R. Ewoldt
Attorney Docket Number	96700/451

Sheet	1	of	1
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	KATZ J. et al, entitled "Mutational Analysis of an Autoantibody: Differential Binding and Pathogenicity," J. Exp. Med., Vol. 180, pp. 925-932, September 1994.	
	2	CWIRLA S., et al, entitled "Peptides on phage: A vast library of peptides for identifying ligands," Proc. Natl. Acad Sci., Vol. 87, pp. 6378-6382, August 1990.	
	3	DEVLIN J. et al, entitled "Random Peptide Libraries: A Source of Specific Protein Binding Molecules," Science, Vol. 249, pp. 404-406, July 1990.	
	4	HOUGHTEN R. et al, entitled "Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery," Nature, Vol. 354, pp.84-86, November 1991.	
	5	CHOW T. et al, entitled "Antibodies to synthetic peptides of human interferon-beta. Use in biosynthetic studies," The Journal of Biol. Chemistry, Vol. 259, (19), pp. 12220-12225, 1984.	
	6	MANHEIMER-LORY A. et al, entitled "Molecular Characteristics of Antibodies Bearing an Anti-DNA-associated Idiotypic," J. Exp. Med., Vol. 174, pp.1639-1652, December 1991.	
	7	YAMADA F. et al, entitled "Purification and Characterization of a Proteinase from Pineapple Fruit, Fruit Bromelain FA21," Vol. 79, pp. 1223-1234, 1976.	
	8	DOKUMOV St. et al, entitled "Serum Gastrin I concentrations of mother and newborn immediately after birth," British Journal of Obstetrics and Gynaecology Vol. 88, pp. 126-128, February 1981.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.